[go: up one dir, main page]

MX2018012230A - Métodos para tratar enfermedades oculares. - Google Patents

Métodos para tratar enfermedades oculares.

Info

Publication number
MX2018012230A
MX2018012230A MX2018012230A MX2018012230A MX2018012230A MX 2018012230 A MX2018012230 A MX 2018012230A MX 2018012230 A MX2018012230 A MX 2018012230A MX 2018012230 A MX2018012230 A MX 2018012230A MX 2018012230 A MX2018012230 A MX 2018012230A
Authority
MX
Mexico
Prior art keywords
methods
eye diseases
treat eye
treat
diseases
Prior art date
Application number
MX2018012230A
Other languages
English (en)
Other versions
MX385698B (es
Inventor
Loudin James
J Mandell Kenneth
Michael Ackermann Douglas
Original Assignee
Oyster Point Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oyster Point Pharma Inc filed Critical Oyster Point Pharma Inc
Publication of MX2018012230A publication Critical patent/MX2018012230A/es
Publication of MX385698B publication Critical patent/MX385698B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Otolaryngology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

En la presente se describen metodos y formulaciones farmaceuticas para tratar afecciones oculares.
MX2018012230A 2016-04-07 2017-04-06 Uso de un compuesto que comprende un grupo pirrolidinilo y pirimidinilo para tratar enfermedades oculares MX385698B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662319648P 2016-04-07 2016-04-07
PCT/US2017/026385 WO2017177024A1 (en) 2016-04-07 2017-04-06 Methods of treating ocular conditions

Publications (2)

Publication Number Publication Date
MX2018012230A true MX2018012230A (es) 2019-03-28
MX385698B MX385698B (es) 2025-03-18

Family

ID=58549326

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018012230A MX385698B (es) 2016-04-07 2017-04-06 Uso de un compuesto que comprende un grupo pirrolidinilo y pirimidinilo para tratar enfermedades oculares
MX2021010399A MX2021010399A (es) 2016-04-07 2018-10-05 Metodos para tratar enfermedades oculares.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021010399A MX2021010399A (es) 2016-04-07 2018-10-05 Metodos para tratar enfermedades oculares.

Country Status (19)

Country Link
US (3) US10709707B2 (es)
EP (2) EP3439661B1 (es)
JP (3) JP7090551B2 (es)
KR (2) KR102485299B1 (es)
CN (3) CN109310692B (es)
AU (1) AU2017248276B2 (es)
DK (1) DK3439661T3 (es)
EA (1) EA201892265A1 (es)
ES (1) ES2893126T3 (es)
IL (3) IL299204A (es)
MX (2) MX385698B (es)
MY (1) MY199237A (es)
NZ (1) NZ746468A (es)
PH (1) PH12018502154A1 (es)
PT (1) PT3439661T (es)
SG (1) SG11201808650QA (es)
TW (2) TWI790997B (es)
WO (1) WO2017177024A1 (es)
ZA (1) ZA201807438B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9145396B2 (en) 2008-12-01 2015-09-29 Targacept, Inc. Synthesis and novel salt forms of (R)-5-((E)-2-pyrrolidin-3ylvinyl)pyrimidine
SG10202011669PA (en) 2014-10-20 2020-12-30 Oyster Point Pharma Inc Methods of treating ocular conditions
MX385698B (es) * 2016-04-07 2025-03-18 Oyster Point Pharma Inc Uso de un compuesto que comprende un grupo pirrolidinilo y pirimidinilo para tratar enfermedades oculares
EP3820443A1 (en) 2018-07-10 2021-05-19 Oyster Point Pharma, Inc. Combinations of positive allosteric modulators and nicotinic acetylcholine receptor agonists for treating ocular conditions
WO2020014217A1 (en) 2018-07-10 2020-01-16 Oyster Point Pharma, Inc. Methods of treating ocular conditions
ES3039903T3 (en) * 2020-04-28 2025-10-27 Oyster Point Pharma Inc Local administration of nicotinic acetylcholine receptor agonists for the inhibition of coronavirus infections
CN117355307A (zh) * 2021-05-07 2024-01-05 奥伊斯特普安生物制药公司 载体与烟碱激动剂的协同疗法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6277855B1 (en) * 2000-04-21 2001-08-21 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with nicotinic acetylcholine receptor agonists
US20030008892A1 (en) 2001-07-09 2003-01-09 Pfizer Inc. Pharmaceutical composition and method of modulating cholinergic function in a mammal
PL374325A1 (en) 2001-11-29 2005-10-17 Pfizer Products Inc. Succinic acid salts of 5,8,14-triazatetracyclo[10.3.1.0 2,11 .0 4,9 ]-hexadeca-2(11),3,5,7,9,-pentaene and pharmaceutical compositions thereof
AU2003269413A1 (en) * 2002-11-01 2004-05-25 Pharmacia & Upjohn Company Llc Nicotinic acetylcholine agonists in the treatment of glaucoma and retinal neuropathy
US7098331B2 (en) 2003-03-05 2006-08-29 Targacept, Inc. Arylvinylazacycloalkane compounds and methods of preparation and use thereof
US20060270592A1 (en) 2004-03-19 2006-11-30 Ophthalmic Research Associates, Inc. Use of neurotransmitters and neuropeptides for the treatment of dry eye diseases and related conditions
EP1802276A1 (en) 2004-10-15 2007-07-04 Pfizer Products Inc. Compositions and methods for intranasal, buccal, sublingual and pulmonary delivery of varenicline
US20090023819A1 (en) 2005-03-22 2009-01-22 Anders Axelsson Use of an Artificial Sweetener to Enhance Absorption of Nicotine
US20110086086A1 (en) 2005-07-26 2011-04-14 Pfizer Inc Transdermal system for varenicline
TWI454262B (zh) 2006-11-02 2014-10-01 Targacept Inc 菸鹼乙醯膽鹼受體亞型選擇性之二氮雜雙環烷類醯胺
KR101107949B1 (ko) 2007-02-02 2012-02-08 화이자 프로덕츠 인코포레이티드 트라이사이클릭 화합물 및 글루코코르티코이드 수용체 조절자로서의 이들의 용도
WO2008157365A2 (en) * 2007-06-15 2008-12-24 Targacept, Inc. Vinylazacycloalkanes for treating neuropathic pain
US20090093446A1 (en) 2007-10-05 2009-04-09 Winston Laboratories, Inc. Method for alleviating keratoconjunctivitis sicca
CL2008003507A1 (es) 2007-11-26 2009-11-27 Neuroderm Ltd Composicion farmaceutica que comprende nicotina y un inhibidor de la desensibilizacion del receptor de acetilcolina nicotinico (nachr) opipramol; kit farmaceutico; dispositivo medico; y uso para tratar una enfermedad o trastorno del sistema nervioso central o periferico.
JP2011513421A (ja) 2008-03-05 2011-04-28 ターガセプト，インコーポレイテッド サブタイプ選択的なジアザビシクロアルカンのアミド
WO2010028011A1 (en) 2008-09-05 2010-03-11 Targacept, Inc. Amides of diazabicyclononanes and uses thereof
WO2010028033A1 (en) 2008-09-05 2010-03-11 Targacept, Inc. Amides of diazabicyclooctanes and uses thereof
CA2738806A1 (en) * 2008-10-14 2010-04-22 Psychogenics, Inc. Nicotinic acetylcholine receptor ligands and the uses thereof
IL266097B (en) * 2008-12-01 2022-07-01 Oyster Point Pharma Inc Mono-orotate acid addition salt of r(–5–)–e(–2–)pyrrolidine––3ylvinyl)pyrimidine
US9145396B2 (en) 2008-12-01 2015-09-29 Targacept, Inc. Synthesis and novel salt forms of (R)-5-((E)-2-pyrrolidin-3ylvinyl)pyrimidine
TW201024283A (en) 2008-12-01 2010-07-01 Targacept Inc Synthesis and novel salt forms of (R)-3-((E)-2-(pyrrolidin-3-yl)vinyl)-5-(tetrahydropyran-4-yloxy)pyridine
AU2010260265A1 (en) * 2009-06-17 2011-12-22 Targacept, Inc. Reversal of L-dopa-induced dyskinesia by neuronal nicotinic receptor ligands
US20110274628A1 (en) 2010-05-07 2011-11-10 Borschke August J Nicotine-containing pharmaceutical compositions
US8821457B2 (en) 2010-09-08 2014-09-02 Johnson & Johnson Vision Care, Inc. Punctal plug containing drug formulation
WO2013057687A2 (en) 2011-10-20 2013-04-25 Novartis Ag Biomarkers predictive of responsiveness to alpha 7 nicotinic acetylcholine receptor activator treatment
US20140357971A1 (en) 2011-11-30 2014-12-04 Diagnostear Ltd. Dry eye diagnostic
SG10202011669PA (en) * 2014-10-20 2020-12-30 Oyster Point Pharma Inc Methods of treating ocular conditions
MX385698B (es) * 2016-04-07 2025-03-18 Oyster Point Pharma Inc Uso de un compuesto que comprende un grupo pirrolidinilo y pirimidinilo para tratar enfermedades oculares

Also Published As

Publication number Publication date
JP2019513759A (ja) 2019-05-30
EP3439661A1 (en) 2019-02-13
JP2024103594A (ja) 2024-08-01
EP3439661B1 (en) 2021-08-04
PT3439661T (pt) 2021-09-30
US20200345734A1 (en) 2020-11-05
JP7090551B2 (ja) 2022-06-24
KR20230010813A (ko) 2023-01-19
AU2017248276A1 (en) 2018-11-22
CN114533737A (zh) 2022-05-27
IL262102B (en) 2022-03-01
MY199237A (en) 2023-10-22
CA3020170A1 (en) 2017-10-12
IL262102A (en) 2018-11-29
IL290069B1 (en) 2023-01-01
DK3439661T3 (da) 2021-10-18
KR102512777B1 (ko) 2023-03-23
CN109310692A (zh) 2019-02-05
US20250000861A1 (en) 2025-01-02
CN114533737B (zh) 2024-05-31
KR102485299B1 (ko) 2023-01-06
IL299204A (en) 2023-02-01
MX385698B (es) 2025-03-18
WO2017177024A8 (en) 2018-11-08
EP3970724A1 (en) 2022-03-23
AU2017248276B2 (en) 2023-07-13
TW202320785A (zh) 2023-06-01
JP2022120125A (ja) 2022-08-17
NZ746468A (en) 2023-06-30
TWI790997B (zh) 2023-02-01
CN114432313A (zh) 2022-05-06
TWI876258B (zh) 2025-03-11
KR20190005859A (ko) 2019-01-16
EA201892265A1 (ru) 2019-04-30
ES2893126T3 (es) 2022-02-08
IL290069B2 (en) 2023-05-01
SG11201808650QA (en) 2018-10-30
PH12018502154A1 (en) 2019-07-08
US10709707B2 (en) 2020-07-14
BR112018070497A2 (pt) 2019-01-29
IL290069A (en) 2022-03-01
ZA201807438B (en) 2024-09-25
CN109310692B (zh) 2022-01-25
MX2021010399A (es) 2022-01-18
ES2893126T8 (es) 2022-05-23
NZ785093A (en) 2024-07-05
WO2017177024A1 (en) 2017-10-12
TW201737917A (zh) 2017-11-01
US20190201397A1 (en) 2019-07-04

Similar Documents

Publication Publication Date Title
PH12019502724A1 (en) Compositions for modulating c9orf72 expression
CL2018001897A1 (es) Composiciones para modular la expresión de sod-1 (divisional solicitud 201602509)
CL2018001152A1 (es) Composiciones y métodos para el tratamiento del cáncer
CL2018003142A1 (es) Moduladores de la vía de estrés integrada
MX2017007148A (es) Bacterias modificadas para tratar enfermedades asociadas con hiperamonemia.
MX2018012230A (es) Métodos para tratar enfermedades oculares.
BR112018010464A8 (pt) formulações farmacêuticas tópicas para tratar condições inflamatórias relacionadas
MX2017016655A (es) Formulaciones oftalmicas de inhibidores de tirosina quinasa, metodos de uso de las mismas y metodos de preparacion de las mismas.
CO2017005784A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
BR112017024384A2 (pt) bactérias modificadas para reduzir hiperfenilalaninemia
EA201691582A1 (ru) Новые фармацевтические препараты
MX2016014140A (es) Composiciones y metodos para modular la expresion de pkk.
MX382033B (es) Compuestos heterocíclicos para utilizarlos en el tratamiento de trastornos mediados por pi3k-gamma.
CO2017007121A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
MX2018012902A (es) Composiciones y métodos para el tratamiento de trastornos de almacenamiento lisosomal y trastornos caracterizados por disfunción lisosomal.
UY37038A (es) Composiciones y métodos para disminuir la expresión de tau
MX2017005064A (es) Metodos para tratar afecciones oculares.
MX385762B (es) Métodos para el control transcripcional objetivo en regiones del super mejorador.
MX2016012784A (es) Composiciones farmaceuticas solidas que comprenden derivados de biopterina y usos de tales composiciones.
EA201792571A1 (ru) Терапевтическое применение l-4-хлорокинуренина
AR107460A1 (es) Gabapentina oftálmica para el tratamiento de las úlceras corneales
PL3515409T3 (pl) Kompleks i kompozycje do leczenia chorób okulistycznych i dermatologicznych
MX2019006886A (es) Métodos para tratar enfermedades asociadas con células linfoides innatas del grupo 2 (ilc2).